All In Biotech

Drug Trial Radar · NCT00140621

A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

A Multicenter Open-label Study of the Safety and Efficacy of α-galactosidase A (R-h α-GAL) Replacement Therapy in Patients With Cardiac Fabry Disease

Last checked: Nov 20, 2026Latest source record: May 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

6

Actual

Start

Jul 2005

Primary completion

Aug 2012

Study completion Aug 2012

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Sep 1, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open label, phase IV study conducted to evaluate the efficacy and safety of agalsidase beta (Fabrazyme \[recombinant form\]) administered by intravenous drip infusion in participants with cardiac Fabry disease. Participants participated for 4 weeks or less in the baseline period and 156 weeks for the treatment period.

Conditions

  • Fabry Disease

Interventions

  • Agalsidase betaDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156Time frame: Baseline to Week 156
  2. Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156Time frame: Baseline to Week 156
  3. Percent Change From Baseline in Left Ventricular Mass (LVM) at Week 156Time frame: Baseline to Week 156
  4. Change From Baseline in LVM at Week 156Time frame: Baseline to Week 156

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Fujita Health University Hospital

    Aichi, Japan

  • Sapporo Medical University Hospital

    Hokkaido, Japan

  • Akune Citizen Hospital

    Kagoshima, Japan

  • Tohoku University Hospital

    Miyagi, Japan

  • Nihon University Itabashi Hospital

    Tokyo, Japan

  • Nihon University Nerima Hikarigaoka Hospital

    Tokyo, Japan

  • Yamanashi Prefectural Central Hospital

    Yamanashi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.